VBL THERAPEUTICS
VBL Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements.
VBL THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Medical Therapeutics
Founded:
2000-01-01
Address:
Or Yehuda, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.vblrx.com
Total Employee:
1+
Status:
Active
Contact:
+97236346450
Email Addresses:
[email protected]
Total Funding:
58.72 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro SPF LetsEncrypt Amazon SSL By Default Global Site Tag HSTS
Similar Organizations
Aer Therapeutics
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.
Arcturus Therapeutics
Arcturus Therapeutics is a clinical-stage company specializing in mRNA medicines and vaccines.
Dimension Therapeutics
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
European Innovation Council
European Innovation Council investment in Grant - VBL Therapeutics
European Innovation Council
European Innovation Council investment in Post-IPO Equity - VBL Therapeutics
ROTH Capital Partners
ROTH Capital Partners investment in Post-IPO Equity - VBL Therapeutics
Israel Innovation Authority
Israel Innovation Authority investment in Grant - VBL Therapeutics
Binder & Partners Ventures
Binder & Partners Ventures investment in Seed Round - VBL Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-05 | VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States |
Official Site Inspections
http://www.vblrx.com Semrush global rank: 6.72 M Semrush visits lastest month: 1.04 K
- Host name: acd89244c803f7181.awsglobalaccelerator.com
- IP address: 75.2.60.5
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "VBL Therapeutics"
VBL Therapeutics
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), clinical stage biotechnology company committed to the discovery, development and commercialization of next-generation, targeted …See details»
About Us - VBL Therapeutics
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), clinical stage biotechnology company committed to the discovery, development and commercialization of next-generation, targeted medicines for difficult-to-treat …See details»
Leadership | VBL Therapeutics - vblrx.com
Senior Vice President, Research & Operations. Read More. The members of VBL's leadership team have extensive experience in the biotechnology and pharmaceutical industry with proven track records in research and …See details»
VBL Therapeutics Announces that S-4 Registration Statement for …
Sep 6, 2023 · Vascular Biogenics Ltd., operating as VBL Therapeutics (Nasdaq: VBLT), is a biopharmaceutical company that has historically focused on developing targeted therapies for …See details»
VBL Therapeutics (Nasdaq:VBLT) - LinkedIn
Biotechnology Research. Modiin, Israel 1,146 followers. Engineering the future of targeted medicines, breaking barriers to develop the next generation therapeutics. View all 16 …See details»
VBL Therapeutics (Nasdaq:VBLT) | LinkedIn
概要. VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases.See details»
VBL Therapeutics and Notable Labs Announce Definitive Merger …
Feb 23, 2023 · Management and Organization. The combined company will be led by Notable’s current management team and will be headquartered in Foster City, California.See details»
VBL Therapeutics Receives FDA Fast Track Designation for
Apr 26, 2022 · Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and …See details»
VBL Therapeutics Reports Full Year 2021 Financial Results
Mar 23, 2022 · TEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company focused on …See details»
Board of Directors - VBL Therapeutics
VBL's board of directors has decades of pharma, biotech and business expertise. Their combined strategic, financial, scientific and medical experience enhances the value we bring, by guiding …See details»
VBL Therapeutics and Notable Labs Announce Definitive Merger …
Feb 23, 2023 · Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s …See details»
VBL Therapeutics Announces that S-4 Registration Statement
Sep 6, 2023 · Vascular Biogenics Ltd., operating as VBL Therapeutics (Nasdaq: VBLT), is a biopharmaceutical company that has historically focused on developing targeted therapies for …See details»
VBL Therapeutics Announces that S-4 Registration ... - Markets …
Sep 6, 2023 · Vascular Biogenics Ltd., operating as VBL Therapeutics (Nasdaq: VBLT), is a biopharmaceutical company that has historically focused on developing targeted therapies for …See details»
VBL Therapeutics Reports Full Year 2021 Financial Results and …
Mar 23, 2022 · TEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company focused on …See details»
VBL Therapeutics Announces Completion of Enrollment in OVAL
Mar 8, 2022 · Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development, and …See details»
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL …
Jul 19, 2022 · TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for …See details»
VBL Therapeutics Reports Full Year 2022 Financial Results and …
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December …See details»
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL
Jul 19, 2022 · TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for …See details»
Neuro-Oncology - vblrx.com
Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with …See details»
VBL Therapeutics Reports First Quarter 2023 Financial
May 15, 2023 · Vascular Biogenics Ltd., operating as VBL Therapeutics (Nasdaq: VBLT), is a biopharmaceutical company that has historically focused on developing targeted therapies for …See details»